Misako Nagasaka

Title(s)Associate Clinical Professor, Medicine
SchoolSchool of Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(714) 456-5153
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 08 15; 28(16):3464-3472. Leddon JL, Gulati S, Haque S, Allen C, Palackdharry S, Mathews M, Kurtzweil N, Riaz MK, Takiar V, Nagasaka M, Patil Y, Zender C, Tang A, Cervenka B, McGrath J, Korn WM, Hinrichs BH, Jandarov R, Harun N, Sukari A, Wise-Draper TM. PMID: 35653116; PMCID: PMC9378458.
      View in: PubMed   Mentions:    Fields:    
    2. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review. Drugs. 2022 Jun; 82(9):979-987. Abuhelwa Z, Alloghbi A, Alqahtani A, Nagasaka M. PMID: 35759121; PMCID: PMC9276583.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Clinical progress of KRAS-targeted therapies: what next? Future Med Chem. 2022 08; 14(15):1107-1110. Nagasaka M, Azmi AS. PMID: 35758004.
      View in: PubMed   Mentions:    Fields:    
    4. African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer. Head Neck. 2022 10; 44(10):2069-2076. Shao YF, Kim S, Cramer JD, Farhat D, Hotaling J, Raza SN, Yoo G, Lin HS, Kim H, Sukari A, Nagasaka M. PMID: 35713967; PMCID: PMC9543059.
      View in: PubMed   Mentions:    Fields:    
    5. The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. Front Oncol. 2022; 12:859892. Liu SV, Nagasaka M, Stefaniak V, Gruver K, Lin Y, Ferry D, Socinski MA, Zhang L. PMID: 35756655; PMCID: PMC9226396.
      View in: PubMed   Mentions:
    6. Preface. Cancer Metastasis Rev. 2022 06; 41(2):245-246. Nagasaka M, Chen G. PMID: 35725839.
      View in: PubMed   Mentions:    Fields:    
    7. Correction to: Connecting the human microbiome and pancreatic cancer. Cancer Metastasis Rev. 2022 Jun; 41(2):333. Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B, Azmi AS. PMID: 35536453; PMCID: PMC9486138.
      View in: PubMed   Mentions:    Fields:    
    8. Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC. Lung Cancer (Auckl). 2022; 13:47-52. Brazel D, Nagasaka M. PMID: 35615402; PMCID: PMC9126226.
      View in: PubMed   Mentions:
    9. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation. Lung Cancer (Auckl). 2022; 13:33-45. Brazel D, Zhang S, Nagasaka M. PMID: 35592355; PMCID: PMC9113513.
      View in: PubMed   Mentions:
    10. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 05 13; 28(10):2020-2029. Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. PMID: 35165101.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    11. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers. Cancer Res Commun. 2022 May; 2(5):342-352. Khan HY, Nagasaka M, Li Y, Aboukameel A, Uddin MH, Sexton R, Bannoura S, Mzannar Y, Al-Hallak MN, Kim S, Beydoun R, Landesman Y, Mamdani H, Uprety D, Philip PA, Mohammad RM, Shields AF, Azmi AS. PMID: 35573474; PMCID: PMC9105196.
      View in: PubMed   Mentions:
    12. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med. 2022 07; 11(13):2541-2549. Wang H, Li ZW, Ou Q, Wu X, Nagasaka M, Shao Y, Ou SI, Yang Y. PMID: 35506567; PMCID: PMC9249987.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022 May; 106:102393. Abuhelwa Z, Alloghbi A, Nagasaka M. PMID: 35472631.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy. Front Med (Lausanne). 2022; 9:879379. Kimura M, Yamauchi J, Sato T, Yagishita N, Araya N, Aratani S, Tanabe K, Horibe E, Watanabe T, Coler-Reilly A, Nagasaka M, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Koseki A, Inoue S, Takata A, Yamano Y. PMID: 35479934; PMCID: PMC9036434.
      View in: PubMed   Mentions:
    15. Connecting the Human Microbiome and Pancreatic Cancer. Cancer Metastasis Rev. 2022 06; 41(2):317-331. Sexton RE, Uddin MH, Bannoura S, Khan HY, Mzannar Y, Li Y, Aboukameel A, Al-Hallak MN, Al-Share B, Mohamed A, Nagasaka M, El-Rayes B, Azmi AS. PMID: 35366155; PMCID: PMC8976105.
      View in: PubMed   Mentions:    Fields:    
    16. Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer. Future Oncol. 2022 May; 18(16):1963-1977. Nagasaka M, Molife C, Cui ZL, Stefaniak V, Li X, Kim S, Lee HY, Beyrer J, Blumenschein G. PMID: 35354280.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression? Lung Cancer (Auckl). 2022; 13:13-21. Nagasaka M, Ou SI. PMID: 35378922; PMCID: PMC8976558.
      View in: PubMed   Mentions:
    18. Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations. Clin Lung Cancer. 2022 06; 23(4):333-344. Harris JP, Fujimoto DK, Nagasaka M, Ku E, Harada G, Keshava H, Mahtabifard A, Longoria J, Patel N, Seyedin S, Simon A, Chen A. PMID: 35256282.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. J Thorac Oncol. 2022 02; 17(2):182-185. Nagasaka M, Ou SI. PMID: 35074224.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    20. Clinical utility of the Bosniak classification version 2019: Diagnostic value of adding magnetic resonance imaging to computed tomography examination. Eur J Radiol. 2022 Mar; 148:110163. Arita Y, Yoshida S, Kwee TC, Edo H, Kufukihara R, Shigeta K, Nagasaka M, Takeshita R, Okamura H, Ueda R, Ishii R, Okuda S, Fujii Y. PMID: 35066340.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P). Viruses. 2022 01 12; 14(1). Yamauchi J, Tanabe K, Sato T, Nakagawa M, Matsuura E, Tsuboi Y, Tamaki K, Sakima H, Ishihara S, Ohta Y, Matsumoto N, Kono K, Yagishita N, Araya N, Takahashi K, Kunitomo Y, Nagasaka M, Coler-Reilly A, Hasegawa Y, Araujo A, Jacobson S, Grassi MFR, Galvão-Castro B, Bland M, Taylor GP, Martin F, Yamano Y. PMID: 35062340; PMCID: PMC8780460.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    22. NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis. Trends Cancer. 2022 03; 8(3):242-258. Nagasaka M, Ou SI. PMID: 34996744.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Lung Cancer. 2022 02; 164:52-55. Nagasaka M, Balmanoukian AS, Madison R, Zhang SS, Klempner SJ, Ou SI. PMID: 35032819.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021 Dec 07; 12(25):2449-2458. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ. PMID: 34917263; PMCID: PMC8664394.
      View in: PubMed   Mentions: 1     Fields:    
    25. Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:133-138. Brazel D, Nagasaka M. PMID: 34880698; PMCID: PMC8648093.
      View in: PubMed   Mentions: 3  
    26. Incidence of Second Primary Lung Cancer After Low-Dose Computed Tomography vs Chest Radiography Screening in Survivors of Head and Neck Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 12 01; 147(12):1071-1078. Cramer JD, Grauer J, Sukari A, Nagasaka M. PMID: 34709369; PMCID: PMC8554690.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat Rev. 2021 Dec; 101:102309. Nagasaka M, Potugari B, Nguyen A, Sukari A, Azmi AS, Ou SI. PMID: 34715449.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    28. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. Clin Lung Cancer. 2022 01; 23(1):52-59. Nagasaka M, Singh V, Baca Y, Sukari A, Kim C, Mamdani H, Spira AI, Uprety D, Bepler G, Kim ES, Raez LE, Pai SG, Ikpeazu C, Oberley M, Feldman R, Xiu J, Korn WM, Wozniak AJ, Borghaei H, Liu SV. PMID: 34801409.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Immune checkpoint inhibitor-induced pneumonitis: Incidence, clinical characteristics, and outcomes. Hematol Oncol Stem Cell Ther. 2021 Oct 18. Banavasi H, Kim S, Alkassis S, Daoud A, Laktineh A, Nagasaka M, Sukari A, Soubani AO. PMID: 34688626.
      View in: PubMed   Mentions: 1     Fields:    
    30. Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:115-122. Zhang SS, Nagasaka M. PMID: 34675734; PMCID: PMC8504654.
      View in: PubMed   Mentions: 3  
    31. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer (Auckl). 2021; 12:103-114. Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M. PMID: 34675733; PMCID: PMC8507417.
      View in: PubMed   Mentions:
    32. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 01 20; 386(3):241-251. Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA, DESTINY-Lung01 Trial Investigators. PMID: 34534430; PMCID: PMC9066448.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    33. Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer. Mol Cancer Ther. 2021 12; 20(12):2577-2584. Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, VanderWalde AM, Mamdani H, Raez LE, Nagasaka M, Pai SG, Socinski MA, Nieva JJ, Kim C, Wozniak AJ, Ikpeazu C, de Lima Lopes G, Spira AI, Korn WM, Kim ES, Liu SV, Borghaei H. PMID: 34518295.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    34. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021 09; 40(3):819-835. Bannoura SF, Uddin MH, Nagasaka M, Fazili F, Al-Hallak MN, Philip PA, El-Rayes B, Azmi AS. PMID: 34499267; PMCID: PMC8556325.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    35. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 2021 10; 160:92-98. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS. PMID: 34482103; PMCID: PMC8853639.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    36. Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021 Nov; 14(11):101191. Ou SI, Nagasaka M, Brazel D, Hou Y, Zhu VW. PMID: 34365220; PMCID: PMC8353359.
      View in: PubMed   Mentions: 1  
    37. Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head Neck. 2021 11; 43(11):3681-3696. Quan DL, Sukari A, Nagasaka M, Kim H, Cramer JD. PMID: 34323332.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    38. p16 positive oropharyngeal small cell cancer: A case report. Oral Oncol. 2021 10; 121:105391. Al Masalmeh N, Kukreja G, Zaiem F, Raza SN, Kim H, Nagasaka M, Sukari A. PMID: 34187735.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    39. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. Lung Cancer. 2021 08; 158:126-136. Zhang SS, Nagasaka M, Zhu VW, Ou SI. PMID: 34175504.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021 09 01; 39(25):2791-2802. Drilon A, Duruisseaux M, Han JY, Ito M, Falcon C, Yang SR, Murciano-Goroff YR, Chen H, Okada M, Molina MA, Wislez M, Brun P, Dupont C, Branden E, Rossi G, Schrock A, Ali S, Gounant V, Magne F, Blum TG, Schram AM, Monnet I, Shih JY, Sabari J, Pérol M, Zhu VW, Nagasaka M, Doebele R, Camidge DR, Arcila M, Ou SI, Moro-Sibilot D, Rosell R, Muscarella LA, Liu SV, Cadranel J. PMID: 34077268; PMCID: PMC8407651.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    41. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021 06 01; 20(1):82. Nagasaka M, Uddin MH, Al-Hallak MN, Rahman S, Balasubramanian S, Sukari A, Azmi AS. PMID: 34074295; PMCID: PMC8170728.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    42. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis. Lung Cancer. 2021 07; 157:147-155. Zhu VW, Zhao JJ, Gao Y, Syn NL, Zhang SS, Ou SI, Bauer KA, Nagasaka M. PMID: 34049720.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    43. Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer. Clin Lung Cancer. 2021 11; 22(6):e842-e850. Fisher A, Kim S, Farhat D, Belzer K, Milczuk M, French C, Mamdani H, Sukari A, Baciewicz F, Schwartz AG, Wozniak A, Nagasaka M. PMID: 34053862; PMCID: PMC8536802.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    44. Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. J Thorac Oncol. 2021 04; 16(4):532-536. Nagasaka M, Ou SI. PMID: 33781444.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Utility of transoral motion-mode ultrasonography to detect tongue fasciculation in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2021 06; 63(6):909-913. Hagiwara Y, Shimizu T, Yanagisawa T, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Soga K, Tsuchihashi Y, Nagasaka M, Sasaki N, Maki F, Shiraishi M, Akiyama H, Hasegawa Y, Yamano Y. PMID: 33675079.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes. Sci Rep. 2021 03 11; 11(1):5639. Elliott A, Saul M, Zeng J, Marshall JL, Kim ES, Nagasaka M, Lenz HJ, Schwartzberg L, Spetzler D, Abraham J, Xiu J, Stafford P, Michael Korn W. PMID: 33707526; PMCID: PMC7952699.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Forget me not - Incorporating standard chemotherapy in an exciting era of clinical trials. Oral Oncol. 2021 05; 116:105160. Nguyen A, Nagasaka M. PMID: 33487535.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    48. Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing. JTO Clin Res Rep. 2021 Feb; 2(2):100132. Ou SI, Xiu J, Nagasaka M, Xia B, Zhang SS, Zhang Q, Swensen JJ, Spetzler D, Korn WM, Zhu VW, Liu SV. PMID: 34589990; PMCID: PMC8474258.
      View in: PubMed   Mentions:
    49. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 05; 16(5):740-763. Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou SI. PMID: 33338652.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    50. How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2020 Dec; 9(6):2521-2534. Xia B, Nagasaka M, Zhu VW, Ou SI, Soo RA. PMID: 33489815; PMCID: PMC7815371.
      View in: PubMed   Mentions: 3  
    51. STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib. JTO Clin Res Rep. 2021 Feb; 2(2):100125. Nagasaka M, Sarvadevabatla N, Iwata S, Ge Y, Sukari A, Klosowski C, Yanagihara R. PMID: 34589985; PMCID: PMC8474477.
      View in: PubMed   Mentions:
    52. A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review. JTO Clin Res Rep. 2021 Jan; 2(1):100116. Zhu VW, Nagasaka M, Madison R, Schrock AB, Cui J, Ou SI. PMID: 34589977; PMCID: PMC8474455.
      View in: PubMed   Mentions: 2  
    53. PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy. Clin Lung Cancer. 2021 01; 22(1):e51-e53. Nagasaka M, Fisher A, Chowdhury T, Ge Y, Sukari A. PMID: 32893122.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    54. Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis. Orphanet J Rare Dis. 2020 07 03; 15(1):175. Yamakawa N, Yagishita N, Matsuo T, Yamauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, Coler-Reilly A, Tsutsumi S, Sato T, Araujo A, Casseb J, Gotuzzo E, Jacobson S, Martin F, Puccioni-Sohler M, Taylor GP, Yamano Y, Japan Clinical Research Group on HAM/TSP. PMID: 32620176; PMCID: PMC7333329.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    55. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations. Mol Oncol. 2020 08; 14(8):1731-1739. Fan Y, Qiu J, Yu R, Cao R, Chen X, Ou Q, Wu X, Shao YW, Nagasaka M, Zhang J, Ou SI. PMID: 32478891; PMCID: PMC7400783.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    56. Is NRG2α Fusion a "Doppelgänger" to NRG1α/β Fusions in Oncology? J Thorac Oncol. 2020 06; 15(6):878-880. Nagasaka M, Ou SI. PMID: 32471560.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    57. Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1-associated myelopathy/tropical spastic paraparesis. Proc Natl Acad Sci U S A. 2020 05 26; 117(21):11685-11691. Nagasaka M, Yamagishi M, Yagishita N, Araya N, Kobayashi S, Makiyama J, Kubokawa M, Yamauchi J, Hasegawa D, Coler-Reilly ALG, Tsutsumi S, Uemura Y, Arai A, Takata A, Inoue E, Hasegawa Y, Watanabe T, Suzuki Y, Uchimaru K, Sato T, Yamano Y. PMID: 32393644; PMCID: PMC7260950.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    58. A user's guide to lorlatinib. Crit Rev Oncol Hematol. 2020 Jul; 151:102969. Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI. PMID: 32416346.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    59. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series). Oral Oncol. 2020 10; 109:104744. Sukari A, Kukreja G, Nagasaka M, Shukairy MK, Yoo G, Lin HS, Hotaling J, Kim H. PMID: 32402656.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    60. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC. J Thorac Oncol. 2020 09; 15(9):1484-1496. Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. PMID: 32360579.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    61. A Catalog of 5' Fusion Partners in ROS1-Positive NSCLC Circa 2020. JTO Clin Res Rep. 2020 Sep; 1(3):100048. Ou SI, Nagasaka M. PMID: 34589944; PMCID: PMC8474457.
      View in: PubMed   Mentions:
    62. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study. Lung Cancer. 2020 07; 145:186-194. Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, Xia B, Zhu VW, Nagasaka M, Yang Y, Li Y, Qiu W, Ying J, Ou SI, Wang Y. PMID: 32336530.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    63. Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep. 2020 Mar; 1(1):100015. Ou SI, Zhu VW, Nagasaka M. PMID: 34589917; PMCID: PMC8474466.
      View in: PubMed   Mentions: 14  
    64. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat Rev. 2020 Mar; 84:101974. Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. PMID: 32014824; PMCID: PMC7041424.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    65. Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases. Lung Cancer (Auckl). 2020; 11:13-18. Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI. PMID: 32021525; PMCID: PMC6970251.
      View in: PubMed   Mentions: 4  
    66. COPD and lung cancer incidence in the Women's Health Initiative Observational Study: A brief report. Lung Cancer. 2020 03; 141:78-81. Nagasaka M, Lehman A, Chlebowski R, Haynes BM, Ho G, Patel M, Sakoda LC, Schwartz AG, Simon MS, Cote ML. PMID: 31958598; PMCID: PMC8898572.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    67. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. Int J Mol Sci. 2019 Dec 29; 21(1). Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y, Mohammad RM, Azmi AS, Sukari A. PMID: 31905765; PMCID: PMC6982268.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    68. Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clin Lymphoma Myeloma Leuk. 2020 05; 20(5):305-311. Bumma N, Nagasaka M, Hemingway G, Miyashita H, Chowdhury T, Kim S, Vankayala HM, Ahmed S, Jasti P. PMID: 32144026.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    69. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-A review. Crit Rev Oncol Hematol. 2020 Jan; 145:102841. Nagasaka M, Sexton R, Alhasan R, Rahman S, Azmi AS, Sukari A. PMID: 31884204.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    70. Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids. J Neurol Neurosurg Psychiatry. 2020 03; 91(3):321-323. Yamauchi J, Sato T, Yagishita N, Araya N, Hasegawa D, Tsutsumi S, Nagasaka M, Coler-Reilly A, Inoue E, Takata A, Hasegawa Y, Yamano Y. PMID: 31662348.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    71. Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan. Orphanet J Rare Dis. 2019 10 21; 14(1):227. Tsutsumi S, Sato T, Yagishita N, Yamauchi J, Araya N, Hasegawa D, Nagasaka M, Coler-Reilly ALG, Inoue E, Takata A, Yamano Y. PMID: 31639014; PMCID: PMC6802124.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    72. Immune checkpoint inhibitors: For how long do we need to release the brakes to achieve the optimum acceleration of immune-mediated anti-tumor response? Oral Oncol. 2020 02; 101:104435. Sukari A, Nagasaka M. PMID: 31635973.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    73. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Clin Lung Cancer. 2020 05; 21(3):247-254. Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI. PMID: 31761448.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    74. A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Lung Cancer (Auckl). 2019; 10:95-105. Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A. PMID: 31572037; PMCID: PMC6750163.
      View in: PubMed   Mentions: 1  
    75. Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. Front Microbiol. 2019; 10:2110. Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Araya N, Yamauchi J, Coler-Reilly ALG, Nagasaka M, Hasegawa Y, Yamano Y, Tsuboi Y. PMID: 31572323; PMCID: PMC6749079.
      View in: PubMed   Mentions: 3  
    76. Complete response with neoadjuvant avelumab in Merkel cell carcinoma - A case report. Oral Oncol. 2019 12; 99:104350. Abdallah N, Nagasaka M, Chowdhury T, Raval K, Hotaling J, Sukari A. PMID: 31277904.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    77. Neuregulin 1 Fusion-Positive NSCLC. J Thorac Oncol. 2019 08; 14(8):1354-1359. Nagasaka M, Ou SI. PMID: 31128291.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    78. Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients. Clin Otolaryngol. 2019 07; 44(4):639-643. Sukari A, Nagasaka M, Diab M, Al Sibai K, Atassi B, Elayoubi JA, Kim S, Küçük Ö. PMID: 30784192; PMCID: PMC6844146.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    79. Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution. Anticancer Res. 2019 Feb; 39(2):781-790. Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, Vaishampayan U, Weise A, Flaherty L, Jang H, Kim S, Gadgeel S. PMID: 30711957; PMCID: PMC6886239.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    80. Unleash the power of the mighty T cells-basis of adoptive cellular therapy. Crit Rev Oncol Hematol. 2019 Apr; 136:1-12. Sukari A, Abdallah N, Nagasaka M. PMID: 30878123.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    81. Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. Lung Cancer (Auckl). 2018; 9:85-90. Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A. PMID: 30498383; PMCID: PMC6207227.
      View in: PubMed   Mentions: 12  
    82. Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity. Front Microbiol. 2018; 9:1651. Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nagasaka M, Suzuki H, Araya N, Coler-Reilly A, Hasegawa Y, Tsuboi Y, Takata A, Yamano Y. PMID: 30090093; PMCID: PMC6068401.
      View in: PubMed   Mentions: 20  
    83. The allure of 'ALUR'. Ann Oncol. 2018 06 01; 29(6):1344-1346. Nagasaka M, Zhu VW, Ou SI. PMID: 29688274.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. Is this really just "fatigue"? A case series of immune-related central adrenal insufficiency secondary to immune checkpoint inhibitors. Clin Case Rep. 2018 Jul; 6(7):1278-1281. Nagasaka M, Abdallah N, Samantray J, Sukari A. PMID: 29988586; PMCID: PMC6028360.
      View in: PubMed   Mentions: 2  
    85. Liquid Biopsy to Identify Actionable Genomic Alterations. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:978-997. Ou SI, Nagasaka M, Zhu VW. PMID: 30231331; PMCID: PMC6865813.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    86. Responses in patients receiving sequential paclitaxel post progression on PD1 inhibitors. Oral Oncol. 2018 05; 80:100-102. Sukari A, Nagasaka M, Abdallah N. PMID: 29605290.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    87. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 2018 01; 18(1):63-70. Nagasaka M, Gadgeel SM. PMID: 29168933; PMCID: PMC6863145.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansPHPublic Health
    88. EGFR-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline EGFR T790M Testing. J Natl Compr Canc Netw. 2017 10; 15(10):1188-1192. Sukari A, Nagasaka M, Wakeling E. PMID: 28982744.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    89. Retreatment With Osimertinib Following Pneumonitis. Clin Lung Cancer. 2018 01; 19(1):e53-e55. Nagasaka M, Gadgeel SM. PMID: 28736180.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    90. Histologic Transformation in NSCLC with PD-1 therapy. J Thorac Oncol. 2017 09; 12(9):e133-e134. Nagasaka M, Pansare RS, Abdulfatah E, Guan H, Tranchida P, Gadgeel SM. PMID: 28502723.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    91. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope. 2017 10; 127(10):2260-2264. Nagasaka M, Zaki M, Issa M, Kim H, Abrams J, Sukari A. PMID: 28271529; PMCID: PMC6853181.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    92. Role of Molecular Profiling in Diagnosis of Papillary Renal-cell Cancer Presenting as Cancer of Unknown Primary Site. Clin Genitourin Cancer. 2017 08; 15(4):e713-e717. Nagasaka M, Kukreja G, Abdulfatah E, Vaishampayan U, Sukari A. PMID: 28024951.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    93. PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report. J Immunother Cancer. 2016; 4:83. Nagasaka M, Zaki M, Kim H, Raza SN, Yoo G, Lin HS, Sukari A. PMID: 27895920; PMCID: PMC5109767.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    94. Cancer Immunology and Immunotherapy. Anticancer Res. 2016 11; 36(11):5593-5606. Sukari A, Nagasaka M, Al-Hadidi A, Lum LG. PMID: 27793882.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    95. Double trouble: a case of concurrent de novo T790M and L858R EGFR mutations in treatment-naive advanced non-small-cell lung cancer. Oncology (Williston Park). 2014 Jun; 28(6):526, 528, 530, 534. Saxena A, Nagasaka M, Li Z, Becker DJ, Levy BP. PMID: 25134330.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    96. Renal protective effects of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. J Hypertens. 2001 Oct; 19(10):1877-82. Kohzuki M, Kamimoto M, Wu XM, Xu HL, Kawamura T, Mori N, Nagasaka M, Kurosawa H, Minami N, Kanazawa M, Saito T, Yoshida K. PMID: 11593110.
      View in: PubMed   Mentions: 18     Fields:    Translation:Animals
    97. Effects of a two-week, hospitalized phase II cardiac rehabilitation program on physical capacity, lipid profiles and psychological variables in patients with acute myocardial infarction. Jpn Circ J. 2001 Feb; 65(2):87-93. Yoshida T, Yoshida K, Yamamoto C, Nagasaka M, Tadaura H, Meguro T, Sato T, Kohzuki MM. PMID: 11216831.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    98. Renal-protective effect of nondepressor dose of cicletanine in diabetic rats with hypertension. Am J Hypertens. 2000 Mar; 13(3):298-306. Kohzuki M, Wu XM, Kamimoto M, Yoshida K, Nagasaka M, Kanazawa M, Yasujima M, Saito T, Sato T. PMID: 10777035.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    99. Comparison of resting beta-methyl-iodophenyl pentadecanoic acid (BMIPP) and thallium-201 tomography using quantitative polar maps in patients with unstable angina. Jpn Circ J. 1997 Feb; 61(2):133-8. Suzuki A, Takada Y, Nagasaka M, Kato R, Watanabe T, Shimokata K, Yasui S. PMID: 9070968.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    100. Allogeneic bone marrow transplantation in children: Tokai experience 1982 to 1984. Tokai J Exp Clin Med. 1985 Jun; 10(2-3):147-58. Kato S, Hoshi N, Nagasaka M, Muranaka S, Yabe H, Kimura M. PMID: 3010509.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    101. Phenotypic reversion of D+ and D- mutant clones in mouse myeloid leukemia. Kobe J Med Sci. 1983 Oct; 29(5):129-42. Maeda S, Chen HL, Nagasaka M, Sugiyama T. PMID: 6583460.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    102. Four cases of t(4;11) acute leukemia and its myelomonocytic nature in infants. Blood. 1983 Jun; 61(6):1174-81. Nagasaka M, Maeda S, Maeda H, Chen HL, Kita K, Mabuchi O, Misu H, Matsuo T, Sugiyama T. PMID: 6340755.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    103. Establishment and cytological characteristics of two in vitro T-cell lines derived from a child with acute lymphatic leukemia and a man with adult T-cell leukemia in Japan. Int J Cancer. 1982 Aug 15; 30(2):173-80. Nagasaka M, Maeda S, Mabuchi O, Takubo T, Nasu K, Wano Y, Sugiyama T. PMID: 6982237.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    104. QT duration and plasma electrolytes (Ca, Na, and K) in uremic patients. Jpn Heart J. 1972 May; 13(3):187-94. Nagasaka M, Yokosuka H, Yamanaka T, Sato T, Nakamura K. PMID: 4538251.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. CLINICAL FEATURE OF MYOCARDIAL INFARCTION IN JAPAN. Jpn Heart J. 1964 Nov; 5:497-511. YOSHITOSHI Y, HANAOKA W, NAGASAKA M, MIYASHITA H, YAMAGUCHI A, ITO T, WATANABE S, OSHIMA M, SHINOHARA Y. PMID: 14250894.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    Misako's Networks
    Concepts (323)
    Derived automatically from this person's publications.
    _
    Co-Authors (8)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _